Free Trial

TScan Therapeutics (TCRX) Competitors

TScan Therapeutics logo
$1.80 -0.04 (-1.90%)
As of 01:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TCRX vs. OLMA, AURA, ATXS, ZYBT, LFCR, BNTC, AVIR, IVA, AARD, and OCGN

Should you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Olema Pharmaceuticals (OLMA), Aura Biosciences (AURA), Astria Therapeutics (ATXS), Zhengye Biotechnology (ZYBT), Lifecore Biomedical (LFCR), Benitec Biopharma (BNTC), Atea Pharmaceuticals (AVIR), Inventiva (IVA), Aardvark Therapeutics (AARD), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry.

TScan Therapeutics vs. Its Competitors

TScan Therapeutics (NASDAQ:TCRX) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

TScan Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TScan Therapeutics$2.82M36.22-$127.50M-$1.09-1.66
Olema PharmaceuticalsN/AN/A-$129.47M-$2.01-2.42

TScan Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500.

In the previous week, TScan Therapeutics had 3 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 3 mentions for TScan Therapeutics and 0 mentions for Olema Pharmaceuticals. TScan Therapeutics' average media sentiment score of 0.59 beat Olema Pharmaceuticals' score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
TScan Therapeutics Positive
Olema Pharmaceuticals Neutral

TScan Therapeutics currently has a consensus price target of $7.80, suggesting a potential upside of 332.13%. Olema Pharmaceuticals has a consensus price target of $24.50, suggesting a potential upside of 404.63%. Given Olema Pharmaceuticals' higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than TScan Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TScan Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Olema Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 4.4% of TScan Therapeutics shares are owned by insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Olema Pharmaceuticals has a net margin of 0.00% compared to TScan Therapeutics' net margin of -2,974.08%. Olema Pharmaceuticals' return on equity of -42.31% beat TScan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TScan Therapeutics-2,974.08% -55.76% -36.56%
Olema Pharmaceuticals N/A -42.31%-38.32%

Summary

TScan Therapeutics beats Olema Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get TScan Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TCRX vs. The Competition

MetricTScan TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$102.15M$2.96B$5.58B$9.01B
Dividend YieldN/A2.44%5.25%4.03%
P/E Ratio-1.6621.4727.5120.20
Price / Sales36.22259.84415.84172.51
Price / CashN/A41.8337.0657.97
Price / Book0.427.788.085.61
Net Income-$127.50M-$55.05M$3.17B$248.50M
7 Day Performance19.54%5.38%3.57%4.92%
1 Month Performance6.80%3.87%3.74%7.42%
1 Year Performance-70.41%5.72%33.78%21.48%

TScan Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TCRX
TScan Therapeutics
2.5915 of 5 stars
$1.81
-1.9%
$7.80
+332.1%
-68.9%$102.15M$2.82M-1.66100News Coverage
Positive News
OLMA
Olema Pharmaceuticals
2.2679 of 5 stars
$4.26
-7.8%
$24.50
+475.1%
-56.7%$316.11MN/A-2.1270Positive News
AURA
Aura Biosciences
1.8866 of 5 stars
$6.26
-0.3%
$22.00
+251.4%
-12.1%$315.69MN/A-3.2950Positive News
ATXS
Astria Therapeutics
1.8054 of 5 stars
$5.36
-3.8%
$30.00
+459.7%
-33.6%$314.34MN/A-2.8730
ZYBT
Zhengye Biotechnology
N/A$5.97
-9.7%
N/AN/A$311.77MN/A0.00278Lockup Expiration
LFCR
Lifecore Biomedical
1.0167 of 5 stars
$8.12
-0.9%
$8.00
-1.5%
+62.0%$303.24M$128.26M-5.60690Positive News
High Trading Volume
BNTC
Benitec Biopharma
2.1699 of 5 stars
$11.70
+3.1%
$23.83
+103.7%
+50.1%$297.94M$80K-7.7520News Coverage
Analyst Forecast
High Trading Volume
AVIR
Atea Pharmaceuticals
2.373 of 5 stars
$3.60
+4.3%
$6.00
+66.7%
+17.9%$295.25MN/A-2.1870News Coverage
High Trading Volume
IVA
Inventiva
2.7761 of 5 stars
$3.19
+4.6%
$10.40
+226.0%
+28.1%$291.77M$9.95M0.00100News Coverage
AARD
Aardvark Therapeutics
N/A$13.52
+1.0%
$33.00
+144.1%
N/A$290.51MN/A0.0018
OCGN
Ocugen
0.9881 of 5 stars
$0.97
-1.4%
$6.00
+518.3%
-37.4%$287.39M$4.05M-5.1180High Trading Volume

Related Companies and Tools


This page (NASDAQ:TCRX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners